{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-000338","form_type":"8-K","ticker":"RARE","cik":"0001515673","company_name":"Ultragenyx Pharmaceutical Inc.","filed_at":"2023-01-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.346782+00:00","generated_at":"2026-06-20T18:44:30.234866+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Ultragenyx reports preliminary 2022 revenue $352-$356M; guides 2023 revenue $425-$450M","bullets":["Preliminary 2022 total product revenue $352M-$356M; Crysvita territories $257M-$258M; Dojolvi $55M-$56M.","2023 revenue guidance $425M-$450M; Crysvita $325M-$340M; Dojolvi $65M-$75M; net cash used ops <$400M.","Year-end 2022 cash ~$900M; non-recurring items included $90M capex, $75M GeneTx acquisition, $30M Evkeeza license.","Pipeline: UX143 Phase 2 data mid-2023; DTX301 Phase 3 start Q1 2023; UX701 Stage 1 enrollment mid-2023; DTX401 Phase 3 data H1 2024.","Crysvita guidance reflects 20% YoY growth; royalties from Europe and North America (starting April 2023) included."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-000338","json":"https://secwatch.observer/filing/0000950170-23-000338.json","markdown":"https://secwatch.observer/filing/0000950170-23-000338.md","text":"https://secwatch.observer/filing/0000950170-23-000338.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1515673/000095017023000338/0000950170-23-000338-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1515673/000095017023000338/rare-20230106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T18:44:30.234866+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"695296bfca58e402a4658c4968adddfa1364f2b7","claim":"Ultragenyx Pharmaceutical Inc. reported 2023 results: revenue $425 million to $450 million. Guidance initiated.","evidence_excerpt":"2023 expected Total Product Revenue guidance between $425 million to $450 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1515673/000095017023000338/0000950170-23-000338-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"2023"},{"label":"Revenue","value":"$425 million to $450 million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"8d731fbbe6bbd4d7dfcc87a916557489d6373fee","claim":"Ultragenyx Pharmaceutical Inc. reported fiscal year 2022 results: revenue $352 million to $356 million.","evidence_excerpt":"Preliminary 2022 Total Product Revenue of $352 million to $356 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1515673/000095017023000338/0000950170-23-000338-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal year 2022"},{"label":"Revenue","value":"$352 million to $356 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}